Outcomes of HLA-mismatched HSCT with TCR??/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity

dc.contributor.authorLum, Su Han
dc.contributor.authorAlbert, Michael H.
dc.contributor.authorGilbert, Patrick
dc.contributor.authorSirait, Tiarlan
dc.contributor.authorAlgeri, Mattia
dc.contributor.authorMuratori, Rafaella
dc.contributor.authorFournier, Benjamin
dc.contributor.authorLaberko, Alexandra
dc.contributor.authorKarakukcu, Musa
dc.contributor.authorUnal, Elrem
dc.contributor.authorAyas, Mouhab
dc.contributor.authorYadav, Satya Prakash
dc.contributor.authorFisgin, Tunc
dc.contributor.authorElfeky, Reem
dc.contributor.authorFernandes, Juliana
dc.contributor.authorFaraci, Maura
dc.contributor.authorCole, Theresa
dc.contributor.authorSchulz, Ansgar
dc.contributor.authorMeisel, Roland
dc.contributor.authorZecca, Marco
dc.contributor.authorIfversen, Marianne
dc.contributor.authorBiffi, Alessandra
dc.contributor.authorDiana, Jean-Sebastien
dc.contributor.authorVallée, Tanja
dc.contributor.authorGiardino, Stefano
dc.contributor.authorErsoy, Gizem Zengin
dc.contributor.authorMoshous, Despina
dc.contributor.authorGennery, Andrew R.
dc.contributor.authorBalashov, Dmitry
dc.contributor.authorBonfim, Carmem
dc.contributor.authorLocatelli, Franco
dc.contributor.authorLankester, Arjan
dc.contributor.authorNeven, Bénédicte
dc.contributor.authorSlatter, Mary
dc.date.accessioned2024-07-05T08:29:07Z
dc.date.available2024-07-05T08:29:07Z
dc.date.issued2024en_US
dc.departmentHKÜ, Sağlık Bilimleri Fakültesi, Hemşirelik Bölümüen_US
dc.description.abstractHLA-mismatched transplants with either in vitro depletion of CD3+ T-cell receptor (TCR)αβ/CD19 (TCRαβ) cells or in vivo T-cell depletion using posttransplant cyclophosphamide (PTCY) have been increasingly used for patients with inborn errors of immunity (IEIs). We performed a retrospective multicenter study via the EBMT registry on 306 children with IEIs undergoing their first transplant between 2010 and 2019 from an HLA-mismatched donor using TCRαβ (n = 167) or PTCY (n = 139). The median age for hematopoietic stem cell transplantation (HSCT) was 1.2 years (range, 0.03-19.6 years). The 3-year overall survival (OS) was 78% (95% confidence interval (CI), 71-84) after TCRαβ and 66% (57-74) after PTCY (P = .013). Pre-HSCT morbidity score (hazard ratio [HR], 2.27; 1.07-4.80, P = .032) and non-busulfan/treosulfan conditioning (HR, 3.12; 1.98-4.92, P < .001) were the only independent predictors of unfavorable OS. The 3-year event-free survival (EFS) was 58% (50%-66%) after TCRαβ and 57% (48%-66%) after PTCY (P = .804). The cumulative incidence of severe acute graft-versus-host disease (GvHD) was higher after PTCY (15%, 9%-21%) than TCRαβ (6%, 2%-9%, P = .007), with no difference in chronic GvHD (PTCY, 11%, 6%-17%; TCRαβ, 7%, 3%-11%, P = .173). The 3-year GvHD-free EFS was 53% (44%-61%) after TCRαβ and 41% (32%-50%) after PTCY (P = .080). PTCY had significantly higher rates of veno-occlusive disease (14.4% vs TCRαβ 4.9%, P = .009), acute kidney injury (12.7% vs 4.6%, P = .032), and pulmonary complications (38.2% vs 24.1%, P = .017). Adenoviremia (18.3% vs PTCY 8.0%, P = .015), primary graft failure (10% vs 5%, P = .048), and second HSCT (17.4% vs 7.9%, P = .023) were significantly higher in TCRαβ. In conclusion, this study demonstrates that both approaches are suitable options in patients with IEIs, although they are characterized by different advantages and outcomes. © 2024 American Society of Hematologyen_US
dc.identifier.citationLum S.H., Albert M.H., Gilbert P., Sirait T., Algeri M., Muratori R., Fournier B., Unal, E. (...). (2024). Outcomes of HLA-mismatched HSCT with TCRαβ/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity. Blood. https://doi.org/10.1182/blood.2024024038.en_US
dc.identifier.doi10.1182/blood.2024024038
dc.identifier.issn00064971
dc.identifier.orcid0000-0002-2691-4826en_US
dc.identifier.pmid38669631
dc.identifier.scopus2-s2.0-85196417938
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1182/blood.2024024038
dc.identifier.urihttps://hdl.handle.net/20.500.11782/4317
dc.identifier.wosWOS:001293213800001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier B.V.en_US
dc.relation.ispartofBlood
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_US
dc.titleOutcomes of HLA-mismatched HSCT with TCR??/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity
dc.typeArticle

Dosyalar

Lisans paketi

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: